Quantitative ELISAs for serum soluble LHCGR and hCG-LHCGR complex: potential diagnostics in first trimester pregnancy screening for stillbirth, Down's syndrome, preterm delivery and preeclampsia. by Chambers, Anne E et al.
Chambers et al. Reproductive Biology and Endocrinology 2012, 10:113
http://www.rbej.com/content/10/1/113RESEARCH Open AccessQuantitative ELISAs for serum soluble LHCGR and
hCG-LHCGR complex: potential diagnostics in first
trimester pregnancy screening for stillbirth, Down’s
syndrome, preterm delivery and preeclampsia
Anne E Chambers1,5, Christopher Griffin2, Samantha A Naif3, Ian Mills3, Walter E Mills1,5, Argyro Syngelaki4,
Kypros H Nicolaides4 and Subhasis Banerjee1,5*Abstract
Background: Soluble LH/hCG receptor (sLHCGR) released from placental explants and transfected cells can be
detected in sera from pregnant women. To determine whether sLHCGR has diagnostic potential, quantitative
ELISAs were developed and tested to examine the correlation between pregnancy outcome and levels of serum
sLHCGR and hCG-sLHCGR complex.
Methods: Anti-LHCGR poly- and monoclonal antibodies recognizing defined LHCGR epitopes, commerical
anti-hCGbeta antibody, together with recombinant LHCGR and yoked hCGbeta-LHCGR standard calibrators were
used to develop two ELISAs. These assays were employed to quantify serum sLHCGR and hCG-sLHCGR at first
trimester human pregnancy.
Results: Two ELISAs were developed and validated. Unlike any known biomarker, sLHCGR and hCG-sLHCGR are
unique because Down’s syndrome (DS), preeclampsia and preterm delivery are linked to both low (less than or
equal to 5 pmol/mL), and high (equal to or greater than 170 pmol/mL) concentrations. At these cut-off values,
serum hCG-sLHCGR together with PAPP-A detected additional DS pregnancies (21%) which were negative by free
hCGbeta plus PAPP-A screening procedure. Therefore, sLHCGR/hCG-sLHCGR has an additive effect on the current
primary biochemical screening of aneuploid pregnancies. More than 88% of pregnancies destined to end in fetal
demise (stillbirth) exhibited very low serum hCG-sLHCGR(less than or equal to 5 pmol/mL) compared to controls
(median 16.15 pmol/mL, n = 390). The frequency of high hCG-sLHCGR concentrations (equal to or greater than 170
pmol/mL) in pathological pregnancies was at least 3-6-fold higher than that of the control, suggesting possible
modulation of the thyrotropic effect of hCG by sLHCGR.
Conclusions: Serum sLHCGR/hCG-sLHCGR together with PAPP-A, have significant potential as first trimester
screening markers for predicting pathological outcomes in pregnancy.
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Human chorionic gonadotrophin (hCG) operates as the
“Master Regulator” of human pregnancy: blastocyst
development, implantation, vascular remodeling, placen-
tal invasion, maternal immunosupression at early preg-
nancy and fetal development are contingent upon
various hCG functions [1]. The cellular signaling trans-
duced by hCG, however, is dependent upon its cognate
receptor LHCGR expressed in the placenta, fetus,
gonads, reproductive tract and in a variety of non-
gonadal tissues [2]. Unlike hCG, very little is known
about how LHCGR modulates its ligand activities in
human pregnancy. Moreover, it is also unknown whether
LHCGR through cognate and non-cognate ligand inter-
actions could regulate the thyrotropic effect of hCG [3]
at early human pregnancy [4]. The conventional animal
model (mouse), which is incapable of producing hCG, is
ineffective in addressing LHCGR dynamics relevant to
human pregnancy.
LHCGR is a G-protein coupled receptor with leuteniz-
ing hormone (LH)/hCG-binding sites at the N-terminus
extracellular domain (ECD), six transmembrane (TM)
domains and short intracellular C-tail [5]. In addition to
mature LHCGR protein, multiple truncated natural var-
iants are produced as a result of alternative splicing [6].
The cell-free soluble LHCGR (sLHCGR) has been
detected in follicular fluid [7] and as hormone-receptor
complex in the Leydig cell culture media [8]. Moreover,
cells transfected with naturally truncated rat [9] and por-
cine [10,11] Lhcgr variants resulted in the secretion of
Lhcgr and hCG-Lhcgr complex proteins into the culture
media. Recent studies [12] revealed that in addition to
the mature LHCGR (Mr, 85-90K), the microvesicles
released from the placental explants under stress con-
tained two additional receptor variants (Mr, 52K and
62K). LHCGR-antibody affinity purification of proteins
from early human pregnancy serum resulted in the de-
tection of three proteins with Mr 50K, 62K and 85K in
western blots (unpublished observations).
The secretion of the soluble LH/hCG receptor from
cultured transfected cells [8-11], placental explants [12]
as well as the identification of a circulating LHCGR
inhibitor protein in serum [13] raised the necessity of
investigating the presence of sLHCGR or LH/hCG-
sLHCGR complexes in the blood serum or other body
fluids. However, the absence of a simple and inexpensive
experimental system for a large-scale quantitative ana-
lysis of sLHCGR in human blood prevented such investi-
gations. Here we describe the development of two
ELISAs that specifically measure sLHCGR and the hCG-
sLHCGR receptor complex in human serum and their
applications in prenatal, first trimester screening for
Down’s syndrome, fetal demise, preeclampsia and pre-
term birth.Methods
Antibodies
Purified LHR29 and LHR74 antibodies were initially pro-
vided by Dr Hugues Loosfelt (INSERM, France) and
subsequently the antibody producing clones were
obtained from ATCC (Clone ID CRL-2685 and CRL-
2686). Antibodies produced in mouse ascites fluid were
purified by Protein A affinity chromatography. The
PG732 is a goat polyclonal antibody raised against a 19
residue LHCGR peptide (LHCGR 209–227; Swissprot:
locus LSHR_HUMAN, accession P22888). The same
peptide was used for affinity purification of the antibody
from ammonium sulphate precipitated PG732 immune
goat serum and was also used to produce mouse mono-
clonal antibody clone 5A10C9. Therefore, 5A10C9 is a
monoclonal version of the PG732 goat anti-LHCGR
polyclonal antibody; LHR H-50 (rabbit) and LH K-15
(goat) antibodies against the N-terminus and internal re-
gion of human LHCGR respectively, were from Santa
Cruz Biotech, USA; anti-hCGbeta monoclonal antibody
(clone 094–10627) was from Acris, Germany; anti-FLAG
peptide monoclonal antibody was from Sigma-Aldrich
(USA). A variety of monoclonal antibodies against hCG
or hCGbeta from various commercial sources were also
tested during the course of assay development. Anti-
bodies were conjugated using a Lightning Link horse-
radish peroxidase (HRP) conjugation kit (Innova
Biosciences, Cambridge, UK) and stored at 4°C for up to
five months.
Expression, cell extraction and affinity purification
of recombinant LHCGR peptides in CHO cells, and western
blotting of recombinant LHCGR and hCGbeta-LHCGR
protein standards for ELISA
Details of the construction of LHCGR cDNA clones,
transfection of Chinese hamster ovary (CHO) cells and
expression of the recombinant proteins have been re-
cently described [12]. Briefly, three LHCGR recombinant
proteins with 3X FLAG epitope tagged at the C-termini
and containing 229, 291 and 318 amino acids of the
LHCGR ECD were independently expressed in CHO
cells in suspension culture. Following 48h of transfec-
tion, the recombinant proteins were extracted either
with lysis buffer (25 mM Hepes pH 7.5, 150 mM NaCl,
1% igepal CA-630 [Sigma-Aldrich], 10 mM MgCl2, 1
mM EDTA, 25 mM NaF, 1 mM Na3VO4, and EDTA-
free protease inhibitor mix [Sigma-Aldrich] or M-PER
reagent [Perbio, Helsinborg, Sweden]. For western blot
analysis of the extracts, anti-FLAG, LHR29, LHR74 pri-
mary antibodies were diluted at a concentration of 1 μg/
mL; PG732 and LHR-H50 were diluted 1 in 5000 and 1
in 2,000, respectively. Both Triton and M-PER lysed
extracts expressing LHCGR291 were used for the devel-
opment of the ELISA assays; however, Triton-lysed
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extracts. The recombinant protein (LHCGR291) was
affinity purified using anti-FLAG M2 affinity column
according to the protocol provided by the vendor (Sigma
Aldrich, USA). The preparation of placental extracts
from early pregnancy (12 wks) for western blots were as
described [12].
The sLHCGR and yoked hCG-sLHCGR complex protein
standards for ELISA
In order to establish the specificity of the sLHCGR
ELISA assay, the LHCGR291 recombinant and mock
(control) transfected CHO cell extracts were initially
employed. The LHCGR291 recombinant protein, which
contains the hCG binding site and binds hCG in plate
assays, was routinely used to generate standard curves
with capture-detection antibodies as described below.
However, the quantitative yield from transfected CHO
suspension cell culture following anti-FLAG affinity
purification was low (<600 μg/L). Therefore, following
initial functionality tests in ELISA, LHCGR ECD was
subsequently produced in bulk via a bacterial expression
system. Other laboratories had shown that the expres-
sion of soluble LHCGR (sLHCGR, N-terminal 336 resi-
dues of the extracellular domain) as a thioredoxin fusion
protein in E. coli carrying mutations in both thioredoxin
reductase (TrxB) and glutathione reductase (gor) genes
[14], had a similar specificity and affinity for hCG as the
intact native LHCGR [15]. Therefore, this protocol was
followed in order to produce the sLHCGR standard cali-
brator for ELISA assays. The protocol for expression of
the sLHCGR fusion protein and affinity purification
through Ni-NTA resin column (Qiagen) were exactly as
described [15]. The estimated molecular mass of the
fused sLHCGR was 57.54 K with pI of 6.15. The affinity
purified protein was >90% pure and the yield varied
from 6.63 to 7.34 mg/L.
For the production of the hCG-sLHCGR standard cali-
brator we employed a different method that aimed to
preserve natural eukaryotic modifications of the hCG
moiety of the final yoked protein. Previous studies [16]
had shown that a tethered single chain hCG and
LHCGR cloned in baculovirus and expressed in insect
cells was functional with respect to ligand-receptor
interaction. Moreover, the yoked hCG-LHCGR ECD is
secreted from insect cells at levels 20-fold higher than
conventional eukaryotic expression systems [16]. Our
goal was to produce yoked hCG-LHCGR single chain
protein containing the epitopes recognized by both
hCGbeta and LHCGR antibodies. Therefore, the open
reading frame encoding the entire 165 amino acids of
hCGbeta was synthesized (ACCESSION AK291552;
CGB165). A linker sequence encoding the hCGbeta
C-terminal peptide (CTP, constituting amino acids 116–145 of hCGbeta) was ligated at the 3’ end of the above
construct (CGB165-CTP). A cDNA clone encoding 115
to 291 amino acid residues of the N-terminal end of
LHCGR ECD was produced. The CGB165-CTP was
ligated to the 5’-end of the modified LHCGR cloned into
p3XFLAG-CMV-14 vector to create 101235–1 clone.
The hCGbeta-LHCGR complex was first expressed in
transfected CHO cells. The specificity of the yoked
hCGbeta-LHCGR protein was established by testing
anti-LHCGR, anti-hCGbeta and anti-FLAG monoclonal
antibody binding of the recombinant and mock trans-
fected CHO extracts in plate assays as well as by western
blotting. Following these initial functionality tests in
ELISA, the yoked protein was subsequently produced in
recombinant baculovirus transfected insect cells.
For baculovirus expression, the cDNA encoding
hCGbeta-CTP-LHCGR (clone 101235–1) with C-terminal
3XFLAG was transferred to a baculovirus vector,
DH10Bac strain was used for the recombinant bacmid
(rbacmid) generation. The positive rbacmid containing
3xFLAG tagged 101235–1 was confirmed by PCR and the
final clone was characterized by DNA sequencing. The
rbacmid was transfected into an sf9 insect cell line, using
Cellfectin, incubated in SF-900 liquid medium for 5–7
days at 27°C. The supernatant was collected and desig-
nated as P1 viral stock. P2 was amplified for later infec-
tion. The results of expression evaluation by western blot
indicated that the target protein was expressed at the
expected relative molecular mass. The recombinant pro-
tein was purified from the supernatant by loading on Flag
M2 affinity gel, and the beads were eluted with TBS
(50 mM Tris–HCl, 150 mM NaCl, pH7.4) containing
200 ng/μl peptide (FLAG: N-Asp-Tyr-Lys-Asp-Asp-Asp-
Asp-Lys-C relative molecular mass, 1013.0). The expres-
sion and purification results indicated that the target
protein was largely released from the cells into the
supernatant. The yield of the yoked hCGbeta-LHCGR
protein was 0.42 mg/L with an estimated purity of
70%. The affinity purified protein was stored in 20%
glycerol at −20°C.
ELISA assays
Ninety-six-well plates (C-well binding capacity 500ng/
well, 8-strip, polystyrene; Greiner Bio-one, Germany)
were coated with 100 μl per well of LHCGR transfected
CHO extracts (for initial ELISA functionality tests) or
with 3 μg/mL affinity purified LHR29 (sLHCGR assay)
or 5A10C9 (hCG-sLHCGRassay) diluted in 50 mM
Carbonate/Bicarbonate buffer pH 9.4 (Thermoscientific/
Pierce, UK) at room temperature (RT) overnight. Following
removal of the antibody, plates were over-coated with 300 μl
per well of 10mM sodium/potassium phosphate buffer at
pH 7.6 containing 5% sucrose (Fluka, UK) and 0.5% bovine
serum albumin (Sigma-Aldrich, UK) for two hours at RT,
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ELISA plates were wrapped and stored at RT and were
stable for six months of use. On the day of use, plates were
blocked for one hour at RT with 100 μl per well of phos-
phate buffered saline pH 7.2 (Thermoscientific/Pierce) con-
taining 1% (v/v) casein concentrate (sdt reagents, Germany)
prior to adding serum, antigen or standards diluted in 25
mM Bicine (Fluka), 50mM Tris pH 7.8, 170mM NaCl and
incubation at RT for 2 h. Following binding, plates were
washed six times with 300 μl per well 2mM Tris Cl pH 7.8,
150mM NaCl, 0.05% Tween 20 prior to incubation with
HRP-conjugated antibodies (LHR29, 5A10C9 or anti-
hCGbeta) diluted in Immunoshot 2 reagent (Cosmo Bio Co.
Ltd, Japan) for 1h. The antigen-binding was detected
by adding TMB (3,30,5,50-tetramethylbenzidine) substrate
(Thermoscientific/Pierce, UK) and the color reaction was
stopped by adding an equal volume of 1N HCl. Plates were
read at 450-620 nm in a standard plate reader. Data were
transferred to Microsoft Excel prior to analysis as described
below.
Patient serum samples
The major aim of this study was a prospective examin-
ation of the association of serum sLHCGR and hCG-
sLHCGR concentrations at early human pregnancy (first
trimester) with adverse pregnancy outcome. The study
was approved by REC West Midlands, as part of
National Research Ethics Services of NHS. Patient infor-
mation and a patient consent form were given to each
patient. As a standard Down’s syndrome screening
requirement, pregnancies at 10–14 wks of gestation
underwent ultrasound examination as well as nuchal scan-
ning where indicated. A combined trisomy screen com-
prising biochemical analysis of free hCGbeta and PAPP-A
was performed on all serum samples. As part of this
standard screening, an aliquot of each serum sample from
consenting patients, was stored at −20°C for further ana-
lysis of sLHCGR and hCG-LHCGR concentrations. A por-
tion of the study was retrospective with regards to Down’s
syndrome; 30 known T21 and 130 control samples
(collected from 2006 to 2009) were obtained from the
Fetal Medicine Foundation (FMF), UK. Unlike PS, the
samples for the retrospective study (RS) were collected in
a referral hospital designated for screening high risk fetal
aneuploidy. Therefore, the samples for retrospective study
obtained from FMF belonged to a high risk pregnancy
group.
Data analysis
The Analysis ToolPak (ATP) software was used to com-
pute means, standard deviation (SD), variance (anova) and
coefficient of variation (CV) for all data sets. For each
ELISA assay, standard curve was generated following
examination of the natural log plot of the optical density(OD) at 450-620 nm for all the standard points, following
removal of the background diluent signal, to ensure that
the points form a straight line. Using the scatter plot func-
tion, a standard curve was created using picomoles per
mL of the standard as Y-value and OD (450-620 nm) on
X-axis. By adding a line of best fit through zero, the equa-
tion and regression of a straight line (y =mx), representing
the exponential, logarithmic portion of a standard curve,
was generated. Generally, the regression, R2 >0.98, was con-
sidered valid. This standard curve and the dilution factors
were used to measure the analyte concentration in a sam-
ple. Correlation testing was performed using the Pearson
product moment method (standard R package). General file
manipulations and data cleaning were implemented using
the Awk programming language or custom programs writ-
ten in Python. The graphical display of the distributions of
data from control and pathological pregnancies were car-
ried out using the ggplot2 package (R statistical software
environment). The detection rates for pathological preg-
nancies were calculated as the proportion of pathological
data points found to lie within the critical regions defined
by the cut-off values set for two analytes. The false positive
rate was calculated as the proportion of all control data
points which were found within the critical regions defined
by the cut-off values. The statistical significance of the dif-
ference in median values for hCGbeta and hCG-sLHCGR
between control and pathological pregnancies were calcu-
lated using a Wilcoxon signed rank test in the R statistical
software package since the data showed a strongly non-
gaussian distribution.
Results
Epitope mapping of LHR 29 monoclonal antibody
Both LHR29 and LHR74 mouse monoclonal antibodies
was raised against bacterially expressed extracelluar do-
main (ECD) and a part of TM domain of LHCGR contain-
ing amino acids residues 75–406 [17]. The specificity
of LHR29 antibody was established by immunopreci-
pitation and immunopurification of 125IhCG-LHCGR
complex, western blot analysis of the immunogen [17]
and LHCGR ECD (amino acids 1–362) expressed in
HEK 293 cells [18] and Dr Axel Themmen, personal
communication.
To map the epitope for LHR29 monoclonal antibody
(Mab), three recombinant LHCGR 318, 291 and 229
proteins fused with 3X-FLAG at the C-termini were
expressed in CHO-S cells [12] and the extracts were
probed with anti-FLAG and LHR29 monoclonal anti-
bodies in western blots (Figure 1a). Unlike anti-FLAG
Mab, LHR29 Mab failed to recognize LHCGR 229 pro-
tein while it reacted with LHCGR 318 and LHCGR 291
(middle panel). As an alternative positive control, a poly-
clonal antibody (PG732) raised in goat and affinity puri-
fied using a 19 amino acid residue LHCGR peptide
Figure 1 Epitope mapping of LHR29 monoclonal antibody. a) Three recombinant proteins containing 229, 291 or 318 amino acid residues of
the LHCGR extracellular domain and C-terminal FLAG-epitope were expressed in CHO cells as described [12]; b), recombinant as well as mock
transfected extracts (no DNA) were resolved in SDS-PAGE, blotted and probed with anti-FLAG, LHR29 and PG732 mono- and polyclonal
antibodies respectively; c), two monoclonal antibodies (LHR74 and LHR29) and one polyclonal (PG732) were used in western blot analysis of
proteins extracted from placental extracts at 12 wks of gestation.
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recombinants. Moreover, LHR H-50 (which recognizes
an epitope corresponding to amino acids 28–77 within
ECD of LHCGR, Santa Cruz Biotechnology, USA and
ref [19]) recognized all three recombinants (data not
shown). Together, these results showed that the epitope
for LHR29 Mab resides within residues 229 and 291
amino acids of LHCGR ECD.
Once the specificity of the LHR29 Mab and PG732
polyclonal antibody were established, the expression of
the LHCGR protein was examined by western blot of
placental extracts from early (12 wks of gestation)
human pregnancy. The LHCGR monoclonal (LHR74
and LHR29) and polyclonal (PG732) antibodies were
used as probes. In addition to mature LHCGR and high
relative molecular mass (Mr) proteins (85K and 100K),
all antibodies reacted with Mr 50K, 62K and 75K iso-
forms (Figure 1b). While the same set of placental pro-
teins were also recognized by LHR-H50 polyclonal
antibody (Santa Cruz Biotech. USA), only mature (Mr
85-90K) and Mr 50K bands reacted with
125I-hCG (19).
None of these bands reacted when the primary antibody
was replaced by isotype-specific mouse IgG [18] and
data not shown. Therefore, at the initial phase of this
study LHR29 and PG732 were used as capture and
detection antibodies, respectively, in ELISA for LHCGRmeasurement. Subsequently, the PG732 polyclonal anti-
body was replaced by 5A10C9 Mab.
The specificity of the LHCGR standard for ELISA
The LHCGR291 recombinant protein with C-terminal 3X
FLAG tag (Figure 1a) which binds hCGbeta (data not
shown) was tested either in cell extracts or as anti-FLAG
affinity purified protein. The antigenic specificity of the re-
combinant was first verified by coating the plates with
serially diluted LHCGR291 M-PER extracts that had been
buffer exchanged using a PD10 column prior to coating,
and reacting with anti-FLAG-HRP (Figure 2a) and serially
diluted LHR29-HRP (Figure 2b). Moreover, the capture of
LHCGR291 protein by LHR29 antibody, subsequently
detected by anti-FLAG-HRP was sensitive to the extract
protein concentration (Figure 2c). The lysates from
CHO-S cells transfected with no DNA were incorporated
as negative controls in these studies (Figure 2a-c). The
specificity and sensitivity of in vitro affinity purified (anti-
FLAG protein A sepharose) LHCGR291 recombinant as
an ELISA standard were further tested. In these experi-
ments, serially diluted LHCGR291 recombinant was cap-
tured and detected in three combinations (Figure 2d-e).
The data shown in Figure 2d (LHR29-PG732-HRP),
Figure 2e (anti-FLAG-LHR29-HRP) and Figure 2f (anti-
FLAG-LHR29-HRP) revealed that linear standard curves
Figure 2 The specificity of sLHCGR ELISA assay. (a-c), demonstrates that LHCGR291 recombinant with C-terminal FLAG-tag specifically reacts
with anti-FLAG and anti-LHCGR (LHR29) monoclonal antibodies; a) when plates coated with increasing amounts of LHR291 and CHO cell extracts
were detected with anti-FLAG antibody and b) when plates coated with increasing amounts of LHR291 and CHO cell extracts were detected with
serially diluted LHR29 antibodies or c), when plates coated with LHR29 antibody captured LHR291 in serially diluted extracts and was detected by
anti-FLAG antibody: (d-f), the concentration-dependent reactivity of the LHCGR protein is shown where d) LHR29-PG732-HRP, e) anti-FLAG-
LHR29-HRP and f) LHR29-anti-FLAG-HRP combinations were used as capture-detection antibodies respectively in ELISA assays specifically
detecting LHCGR291 recombinant protein.
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the assay was established by a variety of controls including
isotype-specific IgGs from rabbit, mouse and goat. These
data led us to conclude that it was experimentally possible
to produce recombinant LHCGR calibrator for quantita-
tive measurement of sLHCGR in human serum by ELISA.
The sLHCGR/hCG-sLHCGR protein standards, calibration
and linear response to sample dilution effect
The yield of anti-FLAG affinity purified recombinant
LHCGR291 protein used to generate standard curves
with capture-detection antibodies described above was
600–800 μg/L. Moreover, our best affinity purified
LHCGR291 standard from cell extracts was 50-60%
pure. Therefore, we turned to bacterially expressed affin-
ity purified LHCGR ECD (see Methods) which consist-
ently had >90% purity (Figure 3a). This LHCGR
standard produced a linear response when LHR29 and
5A10C9 were used as capture and detection antibodies,
respectively as described (12). Unlike sLHCGR, the
hCGbeta tethered to amino acid residues 115–291 of the
LHCGR ECD was expressed in insect cells and the sub-
sequent anti-FLAG affinity purified fusion protein was
~60-70% pure (Figure 3b). Serially diluted hCGbeta-
sLHCGR protein showed linear response when captured
by 5A10C9 and was detected by HRP-conjugated anti-
hCGbeta monoclonal antibody (Figure 3c). This ELISAassay, when tested using three, serially diluted, early preg-
nancy serum samples with known hCG-sLHCGR concen-
trations, showed linear responses to the dilution effect of
each serum sample (Figure 3d). In order to establish the
relation between the two assay systems, both sLHCGR
and hCG-sLHCGR were measured in the same set of
serum samples. The correlation coefficient (r) of the two
assays was 0.88 (Figure 3e), suggesting that primary clin-
ical evaluation of a large cohort study could be carried out
with either one of the two assays. We have primarily used
hCG-sLHCGR assays for clinical studies, because it pro-
vides a direct estimate of the amount of hCG bound to
the circulating receptor.
Sensitivity, precision and accuracy of the ELISA assays
In order to measure the sensitivity of the ELISA assays, the
mean optical density of 16 duplicates of ‘zero standard’
(diluent) plus two standard deviations (SD) values in each
case was extrapolated to the corresponding standard curve.
The sensitivities of the sLHCGR and hCG-sLHCGR assays
were 0.91 and 1.12 pmol/mL, respectively.
The intra-assay percentage coefficient of variation (CV%)
was estimated by repeated measurement (n = 8) of 10 early
pregnancy sera with known concentrations of sLHCGR
(between 6 and 328 pmol/mL) and hCG-sLHCGR
(between 3.4 and 1270 pmol/mL). The standard deviations of
each sample for both analytes are shown (Figure 4a and b).
Figure 3 The sensitivity and relationship of the sLHCGR and hCGbeta-sLHCGR ELISA assays. The recombinant LHCGR and yoked hCG -LHCGR
proteins together with anti-LHCGR and anti-hCG mono- and polyclonal antibodies provide quantitative standard curves in ELISA; a) and b), the coomassie-
stained affinity purified recombinant human a) LHCGR ECD and b) hCGbeta-LHCGR proteins resolved in SDS-PAGE; c and d, both serially diluted protein
standard c) and three serum samples from first trimester pregnancy d) exhibited linear response in ELISA assays where hCG-LHCGR complex was captured by
5A10C9 and was detected by HRP-conjugated anti-hCGbeta monoclonal antibody (clone 094–10627, Acris, Germany): e), shows strong
positive correlation (r = 0.88) between sLHCGR and hCG-LHCGR when the analytes were measured in the same set of serum samples (N, 179).
Figure 4 Precision of the sLHCGR and hCG-sLHCGR ELISA assays. Ten early pregnancy serum samples were used for intra- and inter-assay
validation. Intra-assay variation of 10 sera, mean of octuplicates showing SD for sLHCGR (a) and hCG-sLHCGR (b). Inter-assay variation of 10 sera
tested in duplicate one week apart showing SD for sLHCGR (c) and hCG-sLHCGR (d).
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Table 1 Analytical recovery of defined concentrations of
hCG-sLHCGR and sLHCGR spike into serum samples at
three different known analyte concentrations
Serum
sample
Expected
value Pmol/mL
Observed
value Pmol/mL
Recovery % Mean SD
1 3.89 3.88 99.74 106.94 ± 11.37
7.78 9.34 120.05
15.56 15.72 101.03
2 3.89 3.66 94.087 113.07 ± 17.24
7.78 9.94 127.76
15.56 18.26 117.35
3 3.89 2.94 75.5787 90.53 ± 12.99
7.78 7.71 99.1
15.56 15.08 96.915
4 3.89 3.2 82.262 82.34 ± 2.7
7.78 6.62 85.09
15.56 12.4 79.692
5 3.89 3.86 99.229 90.66 ± 7.5
7.78 6.63 85.219
15.56 13.62 87.532
6 3.89 4.92 126.48 115.1 ± 9.85
7.78 8.5 109.25
15.56 17.05 109.58
7 3.98 2.55 64.07 52 ± 11.9
7.97 4.13 51.82
15.95 6.43 40.313
8 3.98 2.9454 73.857 49.6 ± 23.5
7.97 3.8396 48.139
15.95 4.2867 26.876
9 3.98 3.3188 83.386 74.7 ± 39.4
7.97 8.692 109.06
15.95 5.0572 31.707
Serum samples 1–6, hCG-sLHCGR; serum samples 7–9, sLHCGR.
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trations >10 pmol/mL were 2.3-10.4% and 2.8-9.3% for
sLHCGR and hCG-sLHCGR, respectively.
The inter-assay CV% was estimated by repeated meas-
urement (n = 4) of ten early pregnancy sera in two experi-
ments carried out one week apart with identical sets of
reagents and the same sera. The known sLHCGR and
hCG-sLHCGR concentration range for the sera were 4.2-
120 pmol/mL and 22–339 pmol/mL, respectively. The
inter-assay CV% for sLHCGR and hCG-sLHCGR were
1.0-8.5% and 0.7-9.9%, respectively (Figure 4c and d).
To estimate the analytical recovery in ELISA assays,
known concentrations of purified recombinant hCG-
sLHCGR (3.89-15.56 pmol/mL) and sLHCGR (3.98-
15.95 pmol/mL) were added to serum samples with
known hCG-sLHCGR and sLHCGR concentrations, re-
spectively. Serum samples (spiked or non-spiked) were
assayed in duplicate and the mean recovery and SD of
the analytes for each serum sample are shown in Table 1.
The recovery of spiked hCG-sLHCGR at three different
concentrations from six serum samples were 82.3-115%,
with SD ranging from ±2.7 - ±17.2. The observed mean
hCG-sLHCGR recovery from six samples (serum sam-
ples 1–6, Table 1) was 99.7% (SD, ±10.1). Unlike hCG-
sLHCGR, the analytical recovery of sLHCGR (serum
samples 7–9, Table 1) was between 52–74.7%. A closer
examination suggested that matrix interference with
spike recovery was dependent upon the analyte concen-
tration. Reduced analyte recovery was observed irre-
spective of whether sLHCGR recombinant proteins were
produced in bacteria or CHO cells, suggesting that vari-
able recovery was independent of sLHCGR glycosylation
and other eukaryotic protein modifications. The reduced
spike recovery was not due to inhibitors in the matrix
because the matrix effect was also observed in serially
diluted serum. Since the spike recovery was high at low
concentrations (4–8 pmol/mL, Sample 7–9, Table 1), the
poor recovery at higher sLHCGR concentration could be
caused by altered receptor conformation [20] resulting
in protein aggregation. To distinguish the matrix effect
on endogenous (serum) and exogenously added
sLHCGR, the detection antibody was replaced with anti-
FLAG-HRP which recognizes spiked sLHCGR only. This
study showed that the detection of spiked and not serum
sLHCGR was affected (data not shown).
Quantitative measurement of serum hCG-sLHCGR
in combination with PAPP-A increases the detection
rate in primary Down’s syndrome screening
For investigating the diagnostic potential of sLHCGR and
hCG-sLHCGR in primary screening of trisomic pregnan-
cies, the analyte concentrations in the early pregnancy sera
(11–13.6 wks) from both prospective studies (PS) and
retrospective studies (RS) were measured. The clinicaldata from the PS are shown in Table 2. Interestingly, chro-
mosomally abnormal pregnancies could be detected at
very low (≤5 pmol/mL) and at high (≥170 pmol/mL) con-
centrations, suggesting that hCG-sLHCGR is a unique
biomarker and that within a certain range may have a
physiological role in modulating normal pregnancy. The
distributions of trisomy 21 (T21) and control pregnancies
with combinations of two biochemical markers were plot-
ted (Figure 5) and the detection rate (DR) and the corre-
sponding false positive rates (FR) are shown in Table 3. A
striking observation in these experiments was that >16%
(7 of 43) Down’s syndrome pregnancies had extremely
high circulating hCG-sLHCGR compared to those of
euploid control pregnancies (5%, 24 of 470).
In the prospective study, the detection rate of T21 using
the biochemical combination PAPP-A plus hCGbeta alone
was 46.1% with a false positive rate of 1.7%. In contrast,
Table 2 Circulating hCG-sLHCGR in trisomic pregnancies
Trisomy hCGbeta
MoM
PAPP-A
MoM
NT
MoM
T21
Risk
hCG-LHCGR
Pmol/mL
T21 0.99 0.24 3.50 2.00 0.32
T21 1.66 0.25 2.60 2.00 1.16
T21 1.94 1.08 2.60 24.0 173.73
T21 0.91 0.34 4.10 2.00 1.42
T21 2.05 0.75 3.40 7.00 759.59
T21 1.27 0.50 2.90 3.00 0.58
T21 3.04 0.35 1.90 2.00 0.00
T21 2.12 0.27 4.00 2.00 252.89
T21 2.92 0.36 1.40 63.0 170.74
T21 3.23 0.20 6.40 2.00 0.00
T21 3.92 0.50 1.0 38.0 1.07
*T21 2.829 0.281 3.1 2.00 0.00
T21 0.71 0.22 NA 2.00 2.67
*T17 7.65 2.22 NA 19.00 0.00
T18 1.16 0.14 3.00 2.00 4.36
T18 0.25 0.27 5.80 66.0 1.45
T18 0.78 0.37 NA 2.00 79.37
The multiplicity of median (MoM) for PAPP-A, hCGbeta, Nuchal translucency
(NT), T21 risk are tabulated together with the hCG-sLHCGR concentrations. The
‘*’ and NA indicate live birth and data not available, respectively. T21, T17 and
T18 are trisomy 21, 17 and 18, respectively.
Prospective Study
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Log [hCG-LHCGR pmol/mL]
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Figure 5 Analysis of PAPP-A, free hCGbeta and hCGbeta-sLHCGR com
distribution of PAPP-A, free hCGbeta MoM and hCG-LHCGR values (pmol/m
(RS, n = 150) were plotted. The Down’s pregnancies (T21, n = 13 for PS and
the controls are shown by closed grey triangles in each plot. The cut-off va
≤0.5 MoM and ≥2.0 MoM respectively, as described [21]. The hCG-sLHCGR
pregnancies were set at ≤5 pmol/mL and ≥170 pmol/mL, respectively. All
in each plot are highlighted by shaded boxes.
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http://www.rbej.com/content/10/1/113the detection rate of T21 using the biochemical combin-
ation PAPP-A plus hCG-sLHCGR alone, in the same pro-
spective study, was 84% with a false positive rate of 4.6%.
The detection rate of T21 (Down’s) in the retrospective
study using the biochemical combination PAPP-A plus
hCGbeta alone was 53.3% with a false positive rate of
0.83% However, using the biochemical combination
PAPP-A plus hCG-sLHCGR for detection of T21 in the
RS population did not increase the detection rate com-
pared with the PAPP-A and hCGbeta markers. In the
retrospective study population, the currently used combin-
ation of biochemical markers (PAPP-A plus hCGbeta) was
more effective. These very different T21 detection rates
for the PAPP-A and hCG-sLHCGR combination most
likely reflect the differences between the two (PS and RS)
populations. The prospective study contained individuals
from the general population, whereas the retrospective
study contained selected individuals at high risk of fetal
aneuploidy. The detection rate by PAPP-A plus hCGbeta
in prospective study (46.1% DR with 1.7% FP) reflects the
expected results from a general population [21] rather
than from the high risk samples selected from a retro-
spective study (56.6% DR with 0.83% FP). By combining
the data sets from the prospective and retrospective stud-
ies, the PAPP-A plus hCGbeta detected 58.13% (23/43) of
Trisomy 21 pregnancies with a false positive rate of 4.99%.
However, a combination of PAPP-A and hCG-sLHCGRRetrospective Study
1
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b
plex in trisomic and control pregnancy serum samples. The
L) from a prospective study (PS, n = 363) and a retrospective study
n = 30 for RS) in each plot are shown as dark closed triangles whereas
lues for PAPP-A and free hCGbeta detecting Down’s pregnancies were
has low and high cut-off values. These values for detecting Down’s
data were log-transformed and the regions within these cut-off values
Table 3 Detection rate (DR) and false positive (FP) rate in
each analyte combination for prospective study (PS) and
retrospective study (RS)
Study type No.
Down’s
A B C Additive
effect on
A’
PAPP-A
hCGbeta
PAPP-A
sLHCGR
hCGbeta
sLHCGR
PS 350 + 13 N = 13
DR% 46.1 84.6 53.84 38.46
FP% 1.7 4.6 6 4.6
RS 120 + 30 N = 30
DR% 56.6 46.7 50 13.3
FP% 0.83 4.16 13.3 4.16
Total 470 + 43 N = 43
DR% 53.5 58.13 51.1 20.9
FP% 1.5 4.46 7.9 4.46
The cut-off values used for PAPP-A, hCGbeta and hCG-sLHCGR were ≤0.5
MoM, ≥2.0 MoM and ≤5.0 plus ≥170 pmol/mL, respectively. Additive Effect on
A (PAPP-A and hCGbeta measurement) shows the percentage of additional
T21 pregnancies detected by the hCG-sLHCGR and PAPP-A combination which
had not been detected by PAPP-A and hCGbeta measurements.
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negative for the conventional PAPP-A plus hCGbeta com-
bined screening. Therefore, quantitative measurement of
hCG-sLHCGR together with PAPP-A and free hCGbeta
increased the overall detection rate in the combined data
sets from 58.13% to 72.1% (9/43 T21; 20.9% were add-
itionally detected) with a false positive rate of 4.99%; sug-
gesting that hCG-sLHCGR could be an effective markerFigure 6 Circulating hCG-sLHCGR in preeclampsia, preterm birth and
sLHCGR values (pmol/mL) from the prospective study (PS, n = 350) w
PD and FD, fetal demise) in each plot are shown as dark closed triangles whe
PAPP-A was ≤0.8 MoM, while those for hCG-sLHCGRwere set at ≤5 pmol/mL
within these cut-off values in each plot are highlighted by shaded boxes; b) a
and free hCGbeta with control (n = 30), Down’s syndrome (DS, n = 7) and othfor primary biochemical screening of Down’s syndrome in
both low and high risk populations.
Serum hCG-sLHCGR concentrations in preeclampsia,
preterm delivery and stillbirth at early pregnancy
Serum hCG-sLHCGR concentrations in pregnancies
which were chromosomally normal but had pathological
pregnancy outcomes were also investigated. The hCG-
sLHCGR concentrations with respect to that of PAPP-A
for preeclampsia (PET), preterm delivery (PD) and fetal
demise (FD) are shown in Figure 6a. Unlike PET and
PD, none of the pregnancies with fetal demise had high
hCG-sLHCGR. However, both PET and PD had a pat-
tern of hCG-sLHCGR profile very similar to that of
Down’s syndrome. At ≤0.8 MoM and ≤0.5 MoM cut-off
values for PAPP-A, the detection rates for PET were
58.3% and 41.6% with FP rate of 12% and 4.6%, respect-
ively; at similar PAPP-A cut-off values, the detection
rates for PD were 50% and 23.5% at the FD rates of
12.5% and 4.6%, respectively. At ≤0.8 MoM, the detec-
tion rate for FD was 52.3% with FP rate of 7.1%.
The prevalence of high levels of serum hCG-sLHCGR
(≥170 pmol/mL) in controls, Down’s and pathological
pregnancies, prompted examination of the relative con-
centrations of free hCGbeta in the same set of samples.
The relative levels of hCG-sLHCGR and free hCGbeta in
control, Down’s (DS) and pathological (Path) pregnancies
are shown in Figure 6b and c, respectively. The median
hCG-sLHCGR concentrations in control and pathologicalfetal demise; a), the distribution of PAPP-A MoM and hCG-
ere plotted. Adverse pregnancies (preeclampsia, PET; preterm delivery,
reas the controls are shown by closed grey triangles. The cut-off value for
and ≥170 pmol/mL. All data were log-transformed and the regions
nd c), the relationship between high serum hCG-sLHCGR(>170 Pmol/mL)
er pathological (n = 11) pregnancies are shown.
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(Figure 6b); however, free hCGbeta concentrations, which
positively correlate with total serum hCG (r, 0.54, data not
shown), were significantly higher in DS compared to con-
trol and pathological pregnancies.
Discussion
Here we describe the development of and use of two
ELISA systems for measuring circulating, soluble hCG
receptor (sLHCGR) and hCG-receptor complex (hCG-
sLHCGR) in sera from early human pregnancies. The
specificity, sensitivity and accuracy of these assays were
established using recombinant protein calibrators and
poly-/monoclonal antibodies. Both ELISAs were equally
effective in measuring sLHCGR/hCG-sLHCGR in frozen
serum or plasma samples stored at −20°C for up to 10
years. The sensitivities of the sLHCGR and hCGbeta-
sLHCGR assays described here were insufficient to de-
tect analytes in about 4.6% of the early pregnancy
samples. The current sensitivity (0.9-1.2 pmol/mL) of
these assays could be improved by replacing the HRP-
tag on the detection antibody with chemi-luminescent
or fluorescent-labels.
sLHCGR - a unique biomarker with low and high cut-off
values
Quantitative analysis of sLHCGR and hCG-sLHCGR
complex in early human pregnancy serum samples
showed a wide spectrum of circulating receptor con-
centrations: 0 to >3,500 pmol/mL. By correlation with
pregnancy outcome, it was observed that pregnancies
with a poor outcome had either very low (≤5 pmol/mL)
or significantly high (≥170 pmol/mL) concentrations of
hCGbeta-sLHCGR, in combination with low PAPP-A
(<0.8 MoM). Unlike other pregnancy biomarkers,
sLHCGR appears to be unique due to two cut-off (low
and high) values. While this may reflect the placental
and extra-placental origin of the receptor, it may also be
indicative of a physiological function for sLHCGR that is
defined by concentration range during normal preg-
nancy. The almost ubiquitous expression of LHCGR in
the reproductive organs and certain extragonadal tissues
[2,22] is consistent with the former explanation. Notably,
pregnancies that suffered fetal demise/stillbirth following
first trimester screen only had undetectable and low
serum sLHCGR. These observations could be clinically
applied by using serum sLHCGR/hCG-sLHCGR concen-
trations to predict abnormal outcome at very early
human pregnancy. For example, low PAPP-A (≤0.5
MoM) in combination with high hCGbeta ≥ 2.0 MoM)
are positive in the primary screening for Down’s syn-
drome (21). However, >20% of the Down’s serum sam-
ples (9 of 43) with low PAPP-A (≤0.5 MoM) were
only detectable in combination with hCG-sLHCGR.Therefore, the addition of serum hCG-sLHCGR meas-
urement to the current Down’s screening protocol, that
uses a combination of PAPP-A and free hCGbeta meas-
urement, would increase the biochemical detection rate
of Down’s syndrome. With respect to preeclampsia, pre-
mature birth and fetal demise, measurement of hCGbeta
has very little or no diagnostic application [23]. We have
demonstrated that hCG-sLHCGR plus PAPP-A meas-
urement can identify pregnancies with an adverse out-
come which are chromosomally normal. However, larger
population-based studies, involving both low and high-
risk groups, are required to establish the cut-off values
for serum hCG-sLHCGR/sLHCGR. Furthermore, the
diagnostic potential of sLHCGR systems in combination
with PAPP-A and other early pregnancy markers needs
to be established.
Possible mechanistic basis for the secretion of low and high
sLHCGR
With respect to serum hCG-sLHCGR concentrations,
undetectable or low levels could indicate placental insuf-
ficiency, reduced angiogenesis and perfusion at very
early pregnancy. The majority of pregnancies that are
Down’s or preeclampsia, or those leading to miscarriage
and fetal demise, belong to this category. Low or un-
detectable serum hCG-sLHCGR could be linked to preg-
nancy pathology by two distinct alternative mechanisms.
In the first mechanism, low levels of sLHCGR may re-
flect placental deficiency of the cell-surface bound recep-
tor (low LHCGR expression) and consequent disruption
of physiological hCG signaling. This view is supported by
studies showing a dramatic reduction of full-length
LHCGR expression in Down’s syndrome chorionic villi
compared to chromosomally normal pregnancies [18,24].
It should be noted, however, that the present study failed
to detect any sLHCGR/hCG-sLHCGR in about 4.6% of
the pregnancies and yet, many of these pregnancies have
both normal PAPP-A and free hCGbeta and resulted in
live births with no obvious adverse outcomes for either
mother or baby. One possible explanation could be that
hCG variants in different individuals modulate the recep-
tor dynamics with respect to its release from the tissues as
well as its clearance from the circulation. All sera analysed
in this study were from 10–13 wk gestation. It is possible
that sLHCGR (and hCG-sLHCGR) may have more mean-
ingful diagnostic potential earlier (<10 wks) in the first
trimester.
In the second mechanism, elevated circulating hCG
receptor at early pregnancy might represent placental
pathology (reduced placental perfusion and oxidative
stress) in response to the pro-inflammatory mediators
leading to pathological secretion of sLHCGR. A signifi-
cant number of Down’s pregnancies, preterm delivery
and preeclampsia pregnancies (the present study and
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levels of serum sLHCGR might also be linked to reduced
clearance of hCG when serum concentrations of this
hormone are high. Notably elevated levels of serum hCG
in the second trimester are associated with preeclampsia
[25-29]. The ligand induced secretion of Mr 80K-90K
hCG-sLHCGR complexes into the culture media (8) fur-
ther suggests hormonal regulation of LHCGR secretion.
The impact of high serum sLHCGR in pregnancy could
lead to reduced hCG bioactivity [29], aberrant systemic
vasculo-endothelial and immune activation [30-32]. In
normal pregnancies sLHCGR may act as a reservoir for
easily available hCG. It is interesting to note that there is
a 15-fold difference between the lowest and highest
levels of total hCG that are considered normal in first
trimester pregnancy (20-300K IU/L). The present study
shows an interesting parallel in that normal pregnancies
have a wide range of sLHCGR levels, with a minimum
of a 17-fold difference between low and high (between
10 pmol/mL and 170 pmol/mL).
Could high sLHCGR affect thyroid function in pregnancy?
There could also be a role for serum sLHCGR in modulat-
ing thyroid hormone. High concentrations of hCG
(>50,000 IU/L) at early pregnancy have a thyrotropic effect
in about 18% of pregnancies [4,33,34]. By virtue of its
similarity to the catalytic subunit of thyroid stimulating
hormone (TSH), hCG transiently suppresses the TSH level
and functionally replaces the TSH by directly activating
the TSH receptor in thyroid epithelium [35]. However,
TSH could potentially bind sLHCGR (via a non-cognate
interaction, see ref 3) provided that the free sLHCGR (un-
bound to hCG) concentration is high (spill-over effect).
About 5% of all normal outcome pregnancies tested in the
present study have very high sLHCGR. Therefore, a poten-
tial sLHCGR concentration-dependent binding of TSH in
these pregnancies could have two-fold effects: Inhibition
of the thyrotropic effect of TSH and simultaneous increase
in half life of TSH (hypothyroidism). Further studies are
needed to examine whether subclinical hypothyroidism,
which is strongly associated with preeclampsia [36-38], is
linked to high serum sLHCGR levels and relatively low
total hCG levels, leading to unsaturated sLHCGR at early
pregnancy. Moreover, it has been well established that up
to 12 wks of gestation, the maternal thyroxin is the major
source for activating the fetal CNS receptors. Therefore,
extremely high sLHCGR and low hCG in a very small set
of pregnancies (<2%, Figure 6b) could be linked to im-
paired fetal brain development [39] at the first trimester
of pregnancy.
Possible physiological role for sLHCGR
The two extreme ends of the spectrum of serum
soluble hCG receptor concentrations representingadverse pregnancy outcome (Figures 5 and 6), suggests
intermediate levels of sLHCGR might be important in regu-
lating hCG signaling in normal pregnancy. Microvesicle-
associated LHCGR, released from the placenta [12] could
facilitate hCG signaling at early pregnancy. Microvesicles
released from the tissues, upon fusion with distant target
tissues could transiently confer new properties by repro-
gramming the recipient cells such as maternal vasculo-
endothelial (VE), endometrial epithelial cells (EEC) and
immune cells at the fetal-maternal interface [31]. Exosomes
are constitutively secreted by placental syncytotrophoblasts
throughout the pregnancy [40]. Placental exosome-
mediated transduction of the ligands for the receptors on
the surface of maternal cytotoxic T-cells (Fas-FasL) and NK
cell (NKG2D receptor-ligand) is pivotal to eliciting immune
tolerance at early gestation [41,42]. Moreover, trophoblasts
stimulate endometrial angiogenesis by two alternative
mechanisms: Direct activation of endothelial cells by hCG
and indirect paracrine regulation of EEC by hCG, stimulat-
ing the secretion of VEGF [30-32]. Microvesicles bearing
sLHCGR, following transfer of the receptor to uterine
smooth muscle, EC and EEC, could enhance existing cell-
surface receptor hCG signaling pathways critical for uterine
capillary formation and increased arterial blood flow.
Therefore, reduced secretion of placental sLHCGR could
interfere with utero-placental cross-talk at very early preg-
nancy. The second physiological role of sLHCGR could be
increasing the half-life of the hormone hCG by stabilizing
the hormone-receptor complex for controlled hCG signal-
ing in the target tissues.
Conclusions
Two novel immunoassays for measuring serum/plasma
sLHCGR and hCG-sLHCGR complex in human preg-
nancy have been developed and validated. Clinical evalu-
ation, using serum samples from first trimester
pregnancies, revealed that quantitative analysis of soluble
hCG receptor/ hCG-sLHCGR, together with existing
analytes (free hCGbeta and PAPP-A) could significantly
improve early detection of pregnancy pathology.
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